| Asthma
Qvar RediHaler vs Trelegy Ellipta
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Qvar Redihaler vs Trelegy Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrelegy Ellipta has a higher rate of injection site reactions vs Qvar Redihaler based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trelegy Ellipta but not Qvar Redihaler, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qvar Redihaler
Trelegy Ellipta
At A Glance
Oral inhalation
Twice daily
Inhaled corticosteroid
Oral inhalation
Once daily
ICS/LAMA/LABA
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Asthma (adults and adolescents, >=12 years) 40 to 320 mcg twice daily by oral inhalation, approximately 12 hours apart; starting dose 40 to 80 mcg twice daily for those not on an inhaled corticosteroid; maximum 320 mcg twice daily.
Asthma (pediatric, 4 to 11 years) 40 mcg twice daily by oral inhalation, approximately 12 hours apart; may increase to 80 mcg twice daily after 2 weeks if needed; maximum 80 mcg twice daily.
Chronic Obstructive Airway Disease 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Asthma 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg or 200/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Contraindications
- Primary treatment of status asthmaticus or other acute asthma episodes requiring intensive measures
- Known hypersensitivity to beclomethasone dipropionate or any ingredient in QVAR REDIHALER
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any excipient
Adverse Reactions
Most common (>=3%) oral candidiasis, upper respiratory tract infection, nasopharyngitis, oropharyngeal pain, viral upper respiratory tract infection, sinusitis, pharyngitis, headache, pyrexia
Serious oropharyngeal candidiasis, immunosuppression and risk of infections, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects, glaucoma and cataracts
Postmarketing localized Candida infections, aggression, depression, sleep disorders, psychomotor hyperactivity, suicidal ideation (primarily in children), blurred vision, central serous chorioretinopathy
Most common (>=1%) Headache, back pain, nasopharyngitis, upper respiratory tract infection, bronchitis, dysgeusia, cough, oropharyngeal pain, diarrhea, influenza, sinusitis, oral candidiasis, arthralgia, dysphonia, pneumonia, urinary tract infection, rhinitis, constipation, gastroenteritis
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, intraocular pressure increase, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, anxiety, dysuria, urinary retention
Pharmacology
Inhaled corticosteroid prodrug; beclomethasone dipropionate is rapidly hydrolyzed to the active monoester 17-monopropionate (17-BMP), which inhibits inflammatory cells (mast cells, eosinophils, basophils, lymphocytes, macrophages, neutrophils) and release of inflammatory mediators (histamine, eicosanoids, leukotrienes, cytokines) to reduce airway inflammation in asthma.
TRELEGY ELLIPTA combines fluticasone furoate (ICS), umeclidinium (long-acting muscarinic antagonist), and vilanterol (LABA); fluticasone furoate reduces airway inflammation via glucocorticoid receptor activation, umeclidinium produces bronchodilation through M3 muscarinic receptor inhibition, and vilanterol relaxes bronchial smooth muscle through beta2-adrenergic receptor stimulation and increased cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qvar Redihaler
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (9/12)
Trelegy Ellipta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Qvar Redihaler
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Trelegy Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Qvar Redihaler
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Trelegy Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Qvar Redihaler.
No savings programs available for Trelegy Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Qvar RedihalerView full Qvar Redihaler profile
Trelegy ElliptaView full Trelegy Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.